Drugs /

mik665

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.

Clinical Trials

View Clinical Trials for mik665

Mik665 has been investigated in 4 clinical trials, of which 2 are open and 2 are closed. Of the trials investigating mik665, 3 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

MYC Amplification, MYC Fusion, and MYC Mutation are the most frequent biomarker inclusion criteria for mik665 clinical trials.

Acute myeloid leukemia, diffuse large B-cell lymphoma, and multiple myeloma are the most common diseases being investigated in mik665 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mik665
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Mik665
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mik665 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mik 665, mik-665, mcl-1 inhibitor mik665, s64315
Drug Target(s) [2]:
MCL1
NCIT ID [1]:
C133174

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.